NovaBridge Biosciences Net Assets
NovaBridge Biosciences net assets. Based on the latest financial reports, NovaBridge Biosciences (NBP) has net assets worth $201.10 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($231.54 Million) and total liabilities ($30.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NovaBridge Biosciences (NBP) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $201.10 Million |
| % of Total Assets | 86.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | -95.38% |
| 10-Year Change | N/A |
| Growth Volatility | 254.33 |
Net Assets of NovaBridge Biosciences (2017–2025)
Net assets of NovaBridge Biosciences from 2017 to 2025. This chart illustrates how NovaBridge Biosciences's net assets have evolved over time, based on quarterly financial data. See NovaBridge Biosciences (NBP) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for NovaBridge Biosciences (2017–2025)
The table below shows the annual net assets of NovaBridge Biosciences from 2017 to 2025. For live market cap and overall valuation, see NBP market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $33.02 Million | -97.75% |
| 2024-12-31 | $1.47 Billion | +505.24% |
| 2023-12-31 | $242.58 Million | -91.94% |
| 2022-12-31 | $3.01 Billion | +320.55% |
| 2021-12-31 | $715.33 Million | -87.28% |
| 2020-12-31 | $5.62 Billion | +376.29% |
| 2019-12-31 | $-2.03 Billion | -113.03% |
| 2018-12-31 | $-955.10 Million | -218.59% |
| 2017-12-31 | $-299.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NovaBridge Biosciences's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16739324900.0% over the analyzed period, indicating profitable operations and earnings retention.
NovaBridge Biosciences Net Assets Breakdown (December 2025)
NovaBridge Biosciences net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.86K | 0.01% |
| Other Comprehensive Income | $5.94 Million | 17.99% |
| Other Components | $217.54 Million | 658.90% |
| Total Equity | $33.02 Million | 100.00% |
NovaBridge Biosciences Competitors by Market Cap
The table below lists competitors of NovaBridge Biosciences ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Excel Industries Limited
NSE:EXCELINDUS
|
$117.21 Million |
|
O-TA Precision Industry Co Ltd
TWO:8924
|
$117.22 Million |
|
Bharat Wire Ropes Limited
NSE:BHARATWIRE
|
$117.24 Million |
|
Teo Seng Capital Bhd
KLSE:7252
|
$117.29 Million |
|
STLLR Gold Inc.
TO:STLR
|
$117.03 Million |
|
Western Forest Products Inc
TO:WEF
|
$117.01 Million |
|
Gold Resource Corporation
NYSE MKT:GORO
|
$116.96 Million |
|
Airtel Africa Plc
LSE:AAF
|
$116.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NovaBridge Biosciences's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,468,226,201 to 33,015,325, a change of -1,435,210,876 (-97.8%).
- Net loss of 6,614,616 reduced equity.
- New share issuances of 61,714,000 increased equity.
- Other comprehensive income decreased equity by 237,723,723.
- Other factors decreased equity by 1,252,586,537.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.61 Million | -20.03% |
| Share Issuances | $61.71 Million | +186.93% |
| Other Comprehensive Income | $-237.72 Million | -720.04% |
| Other Changes | $-1.25 Billion | -3793.95% |
| Total Change | $- | -97.75% |
Book Value vs Market Value Analysis
This analysis compares NovaBridge Biosciences's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.14x to 1.27x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $7.06 | $1.01 | x |
| 2018-12-31 | $-16.42 | $1.01 | x |
| 2019-12-31 | $18.38 | $1.01 | x |
| 2020-12-31 | $82.31 | $1.01 | x |
| 2021-12-31 | $9.42 | $1.01 | x |
| 2022-12-31 | $36.46 | $1.01 | x |
| 2023-12-31 | $2.91 | $1.01 | x |
| 2024-12-31 | $18.08 | $1.01 | x |
| 2025-12-31 | $0.79 | $1.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NovaBridge Biosciences utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (-20.03%) is above the historical average (-132.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -72.66% | -2647.41% | 0.01x | 2.50x | $-339.29 Million |
| 2018 | 0.00% | -749.02% | 0.02x | 0.00x | $-307.32 Million |
| 2019 | -135.40% | -4826.77% | 0.02x | 1.62x | $-1.55 Billion |
| 2020 | 8.37% | 30.53% | 0.24x | 1.13x | $-91.80 Million |
| 2021 | -325.94% | -2648.70% | 0.10x | 1.23x | $-2.40 Billion |
| 2022 | -32.16% | 0.00% | 0.00x | 1.35x | $-1.27 Billion |
| 2023 | -604.20% | -32674.02% | 0.01x | 1.52x | $-1.49 Billion |
| 2024 | -11.05% | 0.00% | 0.00x | 1.06x | $-309.08 Million |
| 2025 | -20.03% | 0.00% | 0.00x | 1.13x | $-9.92 Million |
Industry Comparison
This section compares NovaBridge Biosciences's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NovaBridge Biosciences (NBP) | $201.10 Million | -72.66% | 0.15x | $117.16 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About NovaBridge Biosciences
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy… Read more